N

Novoprotein Scientific Inc
SSE:688137

Watchlist Manager
Novoprotein Scientific Inc
SSE:688137
Watchlist
Price: 50 CNY 1.63%
Market Cap: ¥2.3B

Relative Value

The Relative Value of one Novoprotein Scientific Inc stock under the Base Case scenario is 27.83 CNY. Compared to the current market price of 50 CNY, Novoprotein Scientific Inc is Overvalued by 44%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
27.83 CNY
Overvaluation 44%
Relative Value
Price
N
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Novoprotein Scientific Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Novoprotein Scientific Inc
SSE:688137
2.3B CNY 15.8 -35.8 -16.1 -16.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 746 422.5 -160 391.7 -165 649.1 -163 758.9
US
Abbvie Inc
NYSE:ABBV
387.5B USD 6.5 165 16 22.8
US
Amgen Inc
NASDAQ:AMGN
185.5B USD 5.2 26.5 18.9 18.9
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD 5.8 20.8 14.1 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD 10.1 32.4 23.8 24.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 087.6 -532.7 -682 -663.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD 5.6 17.3 16.5 18.7
AU
CSL Ltd
ASX:CSL
87B AUD 3.8 19.8 9.1 11.3
NL
argenx SE
XBRU:ARGX
43.2B EUR 14.1 33.1 67 68.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD 14.7 1 082.9 145.9 177
P/E Multiple
Earnings Growth PEG
CN
N
Novoprotein Scientific Inc
SSE:688137
Average P/E: 174.7
Negative Multiple: -35.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 391.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
165
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
26.5
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
20.8
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
32.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.3
10%
1.7
AU
CSL Ltd
ASX:CSL
19.8
11%
1.8
NL
argenx SE
XBRU:ARGX
33.1
42%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 082.9
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
N
Novoprotein Scientific Inc
SSE:688137
Average EV/EBITDA: 38.9
Negative Multiple: -16.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -165 649.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.9
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
7%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.8
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -682 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
9.1
8%
1.1
NL
argenx SE
XBRU:ARGX
67
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
145.9
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
N
Novoprotein Scientific Inc
SSE:688137
Average EV/EBIT: 44.6
Negative Multiple: -16.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -163 758.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
13%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.8
16%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -663.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.7
13%
1.4
AU
CSL Ltd
ASX:CSL
11.3
11%
1
NL
argenx SE
XBRU:ARGX
68.9
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177
N/A N/A